Santos G F, Deck R R, Donnelly J, Blackwelder W, Granoff D M
Chiron Corporation, Emeryville, California, USA.
Clin Diagn Lab Immunol. 2001 May;8(3):616-23. doi: 10.1128/CDLI.8.3.616-623.2001.
Complement-mediated bactericidal antibodies in serum confer protection against meningococcal disease. The minimum protective titer is estimated to be between 1:4 and 1:8 when measured by the Goldschneider assay performed with human complement, the assay used in the 1960s to establish the correlation between bactericidal antibodies and protection. A more recently described bactericidal assay standardized by an international consortium uses rabbit complement, which is known to augment bactericidal titers. To define a protective titer measured by the standardized assay, we compared bactericidal titers against serogroup C strains measured by this assay to titers measured by the assay described by Goldschneider et al. A titer of > or =1:128 measured by the standardized assay was needed to predict with > or =80% certainty a positive titer of > or =1:4 as measured by the Goldschneider assay. However, the majority of samples with titers of 1:4 measured by the Goldschneider assay had titers of <1:128 when measured by the standardized assay. Therefore, by the results of the standardized assay such persons would be falsely categorized as being susceptible to disease. In conclusion, high bactericidal titers measured with the standardized assay performed with rabbit complement are predictive of protection, but no threshold titer is both sensitive and specific for predicting a positive titer measured by the Goldschneider assay using human complement. Up to 10% of the U.S. adult population lacks intrinsic bactericidal activity against serogroup C strains in serum and can serve as complement donors. Therefore, use of the Goldschneider assay or an equivalent assay performed with human complement is preferred over assays that use rabbit complement.
血清中补体介导的杀菌抗体可提供针对脑膜炎球菌病的保护。当通过用人补体进行的戈德施奈德试验测量时,最低保护滴度估计在1:4至1:8之间,该试验在20世纪60年代用于建立杀菌抗体与保护之间的相关性。一个最近由国际财团标准化的杀菌试验使用兔补体,已知其可提高杀菌滴度。为了确定通过标准化试验测量的保护滴度,我们将通过该试验测量的针对C群菌株的杀菌滴度与戈德施奈德等人描述的试验测量的滴度进行了比较。通过标准化试验测量的滴度≥1:128,才能以≥80%的确定性预测通过戈德施奈德试验测量的阳性滴度≥1:4。然而,大多数通过戈德施奈德试验测量滴度为1:4的样本,通过标准化试验测量时滴度<1:128。因此,根据标准化试验的结果,这些人会被错误地归类为易患疾病。总之,用兔补体进行的标准化试验测量的高杀菌滴度可预测保护作用,但没有阈值滴度对预测用人补体的戈德施奈德试验测量的阳性滴度既敏感又特异。美国多达10%的成年人群血清中缺乏针对C群菌株的固有杀菌活性,可作为补体供体。因此,与使用兔补体的试验相比,首选使用戈德施奈德试验或用人补体进行的等效试验。